Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Heinz Ludwig et al.
Promising new combinations in the treatment of myeloma
The epigenetics of multiple myeloma and the rationale for HDAC inhibitors
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
Advances in acute myeloid leukemia (AML) treatment – updating 7+3